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Abstract
Background—Excess adiposity has been associated with lymphomagenesis, possibly mediated 
by increased cytokine production causing a chronic inflammatory state. The relationship between 
obesity, cytokine polymorphisms and selected mature B-cell neoplasms is reported.
Method—Data on 4979 cases and 4752 controls from nine American/European studies from the 
InterLymph consortium (1988–2008) were pooled. For diffuse large B-cell lymphoma (DLBCL), 
follicular lymphoma (FL) and chronic lymphocytic leukaemia/small lymphocytic lymphoma 
(CLL/SLL), joint associations of body mass index (from self-reported height and weight) and 12 
polymorphisms in cytokines IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), 
IL2 (rs2069762), IL6 (rs1800795, rs1800797), IL10 (rs1800890, rs1800896), TNF (rs1800629), 
LTA (rs909253), and CARD15 (rs2066847) were investigated using unconditional logistic 
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regression. BMI-polymorphism interaction effects were estimated using the relative excess risk 
due to interaction (RERI).
Results—Obesity (BMI≥30kg m−2) was associated with DLBCL risk (OR=1.33, 95%CI 1.02–
1.73), as was TNF-308GA+AA (OR=1.24, 95%CI 1.07–1.44). Together, being obese and 
TNF-308GA+AA increased DLBCL risk almost two-fold relative to those of normal weight and 
TNF-308GG (OR=1.93 95%CI 1.27–2.94), with a RERI of 0.41 (95%CI −0.05,0.84, 
P(interaction)=0.13). For FL and CLL/SLL, no associations with obesity or TNF-308GA+AA, 
either singly or jointly, were observed. No evidence of interactions between obesity and the other 
polymorphisms were detected.
Conclusions—Our results suggest that cytokine polymorphisms do not generally interact with 
BMI to increase lymphoma risk but obesity and TNF-308GA+AA may interact to increase DLBCL 
risk.
Impact—Studies using better measures of adiposity are needed to further investigate the 
interactions between obesity and TNF-308G>A in the pathogenesis of lymphoma.
Keywords
Body mass index; genotype; polymorphism; non-Hodgkin lymphoma
Introduction
Immune dysregulation plays a pivotal role in lymphomagenesis, and epidemiological 
research has tended to concentrate on factors and exposures that interact with the immune 
system. In this regard obesity, which can cause a mild chronic inflammatory state, has been 
suggested to potentially increase the likelihood of lymphoid malignancy development. 
Earlier InterLymph pooled analyses reported that obesity was associated with an increased 
risk of diffuse large B-cell lymphoma (DLBCL) (1,2), and recent meta-analyses provide 
further support for this hypothesis (3,4).
Obesity-related inflammation is thought to result from the pro-inflammatory cytokines and 
chemokines that are produced by adipocytes and macrophages in adipose tissue (5). With 
weight gain, the numbers of adipocytes and macrophages increase as adipose tissue expands, 
increasing production of cytokines such as tumor necrosis factor-α (TNF), leptin, interleukin 
1β (IL-1β) and IL-6, as well as chemokines and acute phase proteins (5). Ideally, to 
investigate whether increased levels of inflammation-related cytokines modulate the 
association between obesity and lymphoid neoplasms, serum levels of cytokines would be 
measured before cancer diagnosis. In the absence of such measurements, single nucleotide 
polymorphisms (SNPs) within genes that express cytokines may act as surrogates that 
indicate variation in risk of lymphoid neoplasms with obesity. Several putative functional 
SNPs in candidate cytokine genes were selected a priori by the InterLymph consortium due 
to their role in lymphoid development, and also- in the pro-/anti-inflammatory pathways 
which may be altered in the obese state. Among these cytokine SNPs, TNF (-308G>A, 
rs1800629), LTA (-252A>G, rs909253) and IL10 (-3575T>A, rs1800890) have been 
associated with lymphoid neoplasms and DLBCL in particular (6–8). There has however 
been little exploration of the relationship between obesity and cytokines on the risk of these 
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malignancies (9–11). Here, we investigate gene-environment interactions between body 
mass index (BMI) and cytokine SNPs using data from case-control studies included in the 
International Lymphoma Epidemiology Consortium.
Materials and Methods
Data Sources
Through the InterLymph consortium, nine case-control studies conducted in the USA and 
five European countries between 1988 and 2008 that had individual level data on BMI and 
cytokine polymorphisms contributed to this pooled analysis. Data were provided via the 
InterLymph Data Coordinating Center (DCC) at the Mayo Clinic, Rochester, which was 
established in 2009 to centrally standardise and harmonise study data so that consistent 
datasets could be produced to expedite pooling projects. Descriptions of the included studies 
have been published (12–20); a brief outline is given in Table 1. Cases were ascertained 
using rapid identification techniques, and controls were randomly selected from population 
registers (6 studies), outpatient clinics (1 study) or hospital inpatients with non-neoplastic 
conditions (2 studies). Each study had the appropriate ethical committees’ approval and 
participants gave their informed consent.
Diagnoses of lymphoid neoplasms were pathologically confirmed and coded to the World 
Health Organisation International Classification for Oncology Version 3 (ICDO3) (7 
studies), REAL (Connecticut) and Working Formulation (UCSF) classifications. Diagnostic 
codes from the different schemas were bridged by the DCC using the same approach as in 
previous InterLymph analyses (21). The analysis here reports on specific lymphoid 
neoplasms: diffuse large B cell lymphoma (DLBCL: ICDO3 codes 9679, 9680, 9684), 
follicular lymphoma (FL: 9690, 9691, 9695, 9698), and chronic lymphocytic leukaemia/
small lymphocytic lymphoma (CLL/SLL: 9670, 9823) and all combined (defined by the 
above ICDO3 codes and 9671, 9673, 9675, 9687, 9689, 9699, 9700, 9701, 9702, 9705, 
9708, 9709, 9714, 9716, 9717, 9718, 9719, 9728, 9729, 9826, 9827, 9832, 9833, 9591, and 
9727). As most studies did not recruit cases with HIV-associated lymphoid neoplasms these 
diagnoses were excluded.
Findings for the individual effects of BMI and cytokine SNPs on the risk of lymphoid 
neoplasms have been reported for the InterLymph studies (1,6–8). In all studies, adult height 
and weight were self-reported, with information on weight requested for one year (NCI-
SEER, UCSF, Connecticut), two years (Mayo Clinic) or five years (UK) before diagnosis or 
interview date; or usual weight (SCALE, EpiLymph). BMI, calculated from weight in 
kilograms and height in metres, was classified according to World Health Organisation 
guidelines as: normal weight (18.5–<25kg m−2); overweight (25–<30 kg m−2) or; obese 
(≥30 kg m−2); the 1% of the study population who were underweight (<18.5kg m−2) were 
excluded from the analyses (22). BMI as a continuous variable was defined as per 5kg m−2 
increase above 18.5 kg m−2. Cytokine SNPs were tested using the Taqman™ platform 
(Applied Biosystems, Foster City, CA, USA), Pyrosequencing™, custom Illumina 
GoldenGate 1,536 SNP oligonucleotide pool (OPA) or iSelect (6–8,14). Twelve SNPs in 
nine candidate genes were investigated: 2q14, IL1A –889C→T (rs1800587; 4 studies, 2195 
cases, 2082 controls), IL1B –511C→T (rs16944; 3 studies, 1843 cases, 1695 controls), and 
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IL1B –31C→T (rs1143627; 4 studies, 2188 cases, 2099 controls); in 2q14.2, IL1RN 
9589A→T (rs454078; 3 studies, 1673 cases, 1598 controls); in 4q26-27, IL2 384T→G 
(rs2069762; 4 studies, 2185 cases, 2085 controls); in 7p21, IL6 –174G→C (rs1800795; 4 
studies, 2203 cases, 2095 controls) and IL6 –597G→A (rs1800797; 3 studies, 1679 cases, 
1591 controls); in 1q31-32, IL10 –3575T→A (rs1800890; 9 studies, 5015 cases, 5061 
controls) and IL10 –1082A→G (rs1800896; 7 studies, 2844 cases, 3328 controls); in 6p21.3, 
TNF–308G→A (rs1800629; 9 studies, 4979 cases, 4752 controls) and LTA252A→G 
(rs909253; 9 studies, 5067 cases, 4879 controls); and in 16q21, CARD15 Ex11-35→C 
(rs2066847; 7 studies, 4267 cases, 4092 controls). SNPs were modelled as dichotomous 
variables assuming dominant inheritance (heterozygous/homozygous variant versus 
homozygous wild type genotypes) as suggested by InterLymph analyses (6–8), to increase 
power and reduce the number of statistical tests. Due to potential ethnic differences in body 
fat and SNP distributions, analyses were restricted to persons who described themselves as 
of White European descent.
Statistical Analyses
Risk estimates were calculated using unconditional logistic regression adjusted for study, 
sex and age. Main and joint associations with BMI and each SNP on the risk of lymphoid 
neoplasms were estimated. Additive interactions between SNP and BMI were estimated by 
the relative excess risk due to interaction (RERI). When BMI was a categorical variable, the 
95% confidence intervals (CI) for RERI were estimated using likelihood-based 95%CI (23). 
For BMI as a continuous variable, 10000 bootstrapping samples (without replacement) of 
the original sample size were taken from the dataset and the 95%CIs were the 2.5th and 
97.5th centile of the bootstrap sampling distribution (24).
Analyses were repeated for DLBCL, FL and CLL/SLL, and all controls were used 
irrespective of the individual studies’ matching techniques. Heterogeneity between study-
specific risk estimates was considered present when a test for interaction between the 
variable of interest and study was statistically significant (p-value<0.05). Potential sources 
were investigated using sensitivity analyses by: study design (population- or hospital-based); 
diagnosis classification; participation rates; continent; proportions of cases and controls with 
SNP data; whether the controls’ SNP data were in Hardy-Weinberg equilibrium; or where 
there was no relationship between obesity and the SNP among controls. All analyses were 
conducted using Stata 13.1.
Results
Data were received for a total of 5844 cases and 6167 controls. The majority of cases were 
diagnosed with mature B-cell neoplasms (90%), comprising DLBCL (28%), FL (23%), 
CLL/SLL (19%) and other B-cell subtypes (20%); 6% were T-cell in origin and 4% had no 
immunophenotype or subtype recorded. A higher proportion of cases were men (53%) and 
the median age at diagnosis was 60 years. Controls were more likely to be women, of 
younger age, and higher socioeconomic status than cases (Table 2).
Table 3 shows findings for the twelve cytokine polymorphisms among the subsets of 
subjects who had genotype data for each SNP as well as BMI data. Positive associations 
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were found with DLBCL for TNF-308G>A (odds ratio (OR)=1.24, 95% confidence interval 
(CI) 1.07–1.44), IL10-1082A>G (OR=1.14, 95% CI 1.00–1.31) and CARD15 Ex11-35>C 
(OR=1.25, 95%CI 1.10–1.56); with FL for the two IL10 SNPs (IL10-3575T>A: OR=1.15, 
95%CI 1.04–1.28; IL10-1082A>G: OR=1.10, 95%CI 1.05–1.15); and with CLL/SLL for 
IL1RN 9589A>T (OR=1.50, 95%CI 1.17–1.91). A few negative associations were also 
found for FL with IL6 -597G>A (OR=0.81, 95%CI 0.78–0.85) and LTA 252A>G (OR=0.93, 
95%CI 0.87–0.99); and for CLL/SLL with IL1B -511C>T (OR=0.84, 95%CI 0.81–0.87). 
Table 4 shows findings between DLBCL, FL and CLL/SLL and being overweight or obese 
for the subsets of subjects with data for the five positively associated polymorphisms; 
findings for BMI in the subsets for the other seven polymorphisms were similar (data not 
shown). Risk estimates were increased for DLBCL among obese individuals compared to 
those of normal weight in subsets with TNF-308G>A (OR=1.33, 95% CI 1.02–1.73), 
IL10-1082A>G (OR=1.39, 95% CI 1.12–1.73) and CARD15 Ex11-35>C (OR=1.41, 95%CI 
1.04–1.91) data. For FL, there was no evidence that being obese increased risk (OR=1.00, 
95%CI 0.81–1.24; OR=1.13, 95%CI 0.91–1.40 in the IL10-3575T>A and IL10-1082A>G 
subsets for example); while for CLL/SLL, some decreased associations with obesity were 
found (OR=0.80, 95%CI 0.69–0.93 in the IL10 -3575T>A subset for example).
For DLBCL, the only subtype associated with obesity, tests for departure from additive 
interaction showed weak evidence for an additional effect of obesity and TNF-308GA+AA 
on DLBCL risk (P(interaction)=0.13); there was no evidence for the other two 
polymorphisms positively associated with this subtype (P(interaction)=0.77 and 0.85 for 
IL10-1082A>G and CARD15 Ex11-35>C, respectively). Table 5 shows joint associations of 
BMI and TNF-308G>A on DLBCL risk, with the relative excess risks due to interaction 
(RERI); for completeness, joint associations and RERIs of BMI and the other 
polymorphisms for all three subtypes are given in Supplementary Tables 1 and 2 for 
categorical and continuous BMI respectively. For DLBCL, risk estimates were increased 
among those who were overweight or obese irrespective of TNF-308G>A status (overweight 
& GG: OR=1.21, 95%CI 1.02–1.44; overweight & GA+AA: OR=1.31, 95%CI 1.00–1.71; 
obese & GG: OR=1.25, 95%CI 1.00–1.56). However, being both obese and having the 
TNF-308A allele almost doubled the risk estimate compared to persons of normal weight 
who did not carry the A allele (OR=1.93 95%CI 1.27–2.94); an additional risk from being 
obese and having TNF-308A variant rather than having either risk factor alone was 
suggested (RERI=0.41, 95%CI −0.05, 0.84). Similarly, increased trends with 5kg m−2 
increase in BMI above 18.5kg m−2 were seen in homozygous wild types and variant 
TNF-308A carriers (OR=1.14, 95%CI 1.07–1.22; OR=1.19, 95%CI 1.12–1.27 respectively). 
The corresponding RERI of 0.05 (95%CI −0.005–0.08) suggests that with every 5kg m−2 
rise in BMI, the risk of DLBCL is 0.05 more than if there was no interaction.
Joint associations of BMI and TNF-308G>A genotype on DLBCL risk were not consistent 
across studies (P(heterogeneity)=0.02). Associations were similar among North American 
studies, with evidence of additive interaction (RERI=1.27, 95%CI 0.48,2.08); but not among 
European studies (RERI=−0.25, 95%CI −0.84,0.28) (Table 6). Heterogeneity was present 
among studies that were population-based; which used the ICDO3 disease classification; 
where participation rates were 70% or more; where 90% or more of subjects were 
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genotyped; where control distributions of TNF genotypes were in HWE; or where BMI and 
TNF-308G>A genotypes were not correlated among controls. In these groupings, the risk 
estimates of being obese and having TNF-308GA+AA genotype tended to be similar, and 
RERIs were all above zero, although most were not statistically significant.
Discussion
This InterLymph analysis of the joint associations of BMI and cytokine polymorphisms on 
the risk of the three most common lymphoid neoplasms found some evidence of interaction 
between obesity and TNF-308G>A (rs1800629). For DLBCL, the risk was greatest among 
those who were obese and carried the TNF-308A allele, although risk was also increased 
among the overweight regardless of TNF status. The associations showed some variation 
between studies, but these differences were not explained by study design, disease 
classification or other factors. On the other hand, being obese and carrying TNF-308A did 
not increase the risk of either FL or CLL/SLL. Besides TNF-308G>A, other cytokine SNPs 
in IL1A (rs1800587), IL1B (rs16944, rs1143627), IL1RN (rs454078), IL2 (rs2069762), IL6 
(rs1800795, rs1800797), IL10 (rs1800890, rs1800896), LTA (rs909253), and CARD15 
(rs2066847) showed little evidence of altering the NHL risk associated with being 
overweight.
Since publication of the InterLymph pooled analysis of BMI, where we reported that obesity 
increased DLBCL risk (1), several studies including cohorts have also found this 
relationship (25–29) while others have not (11,30–36). In summarising published data for 
DLBCL and obesity, two meta-analyses have noted an increased risk (3,4), the latest 
including all but the most recent publications (27,28). Unfortunately, however, several 
studies which reported no association with total NHL did not stratify their data by subtype 
(32,37–39). To further explore the mechanisms underlying the relationship between obesity 
and lymphoma, chronic inflammation involving cytokine production is one possible 
pathway that has been investigated mostly by examining SNPs (9–11), although the 
functional roles for some are not yet conclusive (40). One study measured pre-diagnosis 
serum levels of cytokines and found no association between TNF levels and NHL among 
either normal or over- weight persons (9). When examining SNPs in TNF, Wang and 
colleagues noted an excess risk of DLBCL among obese individuals carrying the TNF-308A 
allele and, although Chen et al did not report joint associations, a similar finding among 
overweight women is suggested (crude OR=1.8, 95%CI 1.0–3.2) (10,11). To our 
knowledge, these are the only studies to have investigated cytokine SNPs in relation to the 
effect obesity may have on lymphoma risk, and both are included in this pooled analysis.
TNF has been implicated in the relationship between obesity and several other cancers 
including breast, endometrium and gastrointestinal (41–43); the promotion of tumour cell 
proliferation through activation of nuclear factor κB (NFκB) being suggested as the most 
likely explanation (44). In obesity, B cells, T cells and macrophages infiltrate the expanding 
adipose tissue, and not only lead to, but also maintain, a chronic inflammatory state (5). The 
macrophages secrete most of the TNF produced by adipose tissue, which escapes into 
circulation to bind to and activate its receptor TNFR, which is expressed in all human tissues 
(5,41). TNF activates IL6 in adipose tissue and downstream of both cytokines are the NFκB 
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and STAT3 cycles. These pathways have important roles in lymphocyte development, 
function and survival, and deregulation of these cycles are seen in lymphoid malignancies 
including DLBCL, the most common aggressive subtype examined here (26). Obesity-
related lymphomagenesis is likely to be complex involving the actions of additional pro-
inflammatory cytokines and immuno-modulatory mediators that trigger downstream targets 
that promote the clonal expansion and transformation of B cells with premalignant lesions. 
Further studies will be needed to investigate possible disease mechanisms.
When assessing gene-environment interactions, differential misclassification can bias the 
interaction estimate in either direction (45). Our data may not be free from differential case-
control participation and reporting. Among controls, obesity-related health problems may 
have influenced their participation and for cases, although rapid ascertainment techniques 
were employed, those with poor survival, which may be related to different degrees of 
adiposity (46), could have been missed. Our anthropometric data were self-reported and 
BMI could be biased towards “normal” weight since respondents tend to overestimate their 
height and underestimate their weight to varying degrees dependent on their gender and age 
(47). Cases’ responses could also have been influenced by weight loss associated with 
lymphoma, although several studies attempted to compensate for this by requesting weight 
at a year or more before diagnosis. The effect of participation bias on our finding of an 
interaction will be limited if obesity and TNF-308G>A are associated in the general 
population. TNF-308G>A SNP has been suggested to be related- albeit weakly - to obesity, 
but the mechanism for TNF gene involvement in obesity pathogenesis is unclear (48). If 
there is an association, persons carrying the variant allele may be under- (or over-) 
represented in our data if body fatness is related to participation, or the stratum-specific 
frequencies on gene and BMI category could be inaccurate, biasing the interaction estimate 
in either direction. Among our controls TNF genotype and BMI overall were not correlated 
in all but two of our studies (NCI-SEER, EpiLymph-Spain); the removal of these did not 
alter our findings.
Strengths of our study include its large sample size, giving the potential to examine 
interactions and explore differences in interactions among the most common lymphoid 
neoplasms. Obesity prevalence varies across countries, which could relate differently to 
subjects’ participation and responses in the studies included. Most studies had not published 
on this topic before, and while data were a subset of studies and subjects included in the 
main effects analyses, the risk estimates for BMI and SNPs were consistent with those 
published previously (1,6–8). A reduced risk of CLL/SLL with obesity was found in some 
subsets of data, which could relate to disease-related weight loss; but in larger InterLymph 
datasets, no obesity associations for CLL/SLL have been reported (1). Other limitations are 
the low power to assess interactions in less common lymphoid neoplasms, and some SNPs 
which were tested in only a few studies. Indeed, statistically significant interactions were 
found with SNPs genotyped in all nine studies, and others with fewer may have shown an 
effect had we had more data. Many other candidate cytokine SNPs were not associated with 
lymphoid neoplasms, and so it is not surprising that no joint association was found between 
obesity and these SNPs. BMI in this analysis related to weight at older age and there was no 
evidence that associations were different among those aged under, or over, 65 years; data on 
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BMI in young adulthood- which has been associated with DLBCL (2,31)- were too sparse. 
As for generalizability, our findings may not translate to all populations as our subjects were 
Caucasian and resident in developed nations.. Furthermore, the body mass index was 
developed to estimate body fat in Caucasians of working age and so may not be applicable 
to other groups; no other indicators such as waist-hip ratio were available. There is certainly 
variation in obesity rates worldwide (49), and also the distribution of TNF-308G>A 
genotypes and those of the other SNPs studied here differ between populations too (50).
In conclusion, we found some evidence of interaction between TNF-308G>A and BMI on 
the risk of DLBCL. The increased risk among persons carrying the variant TNF-308A allele 
and being obese was not necessarily consistent across studies however, and the possibility 
that differential biases affected the findings cannot be ruled out. One way to potentially 
reduce these biases is to examine gene-environment associations in large cohort studies 
using more specific measures of adiposity such as total body fat, and obtaining data on 
circulating levels of TNF and other cytokines. Furthermore, within InterLymph, genome-
wide association scans are now completed for more studies than included here (51), and 
findings from these may identify other adipose tissue-related cytokines and adipokines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Financial Support:
Studies that contributed data to this pooled analysis were supported by: NCI contracts N01-PC-65064, N01-
PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105 and the Intramural Research Program of the National 
Cancer Institute, National Institutes of Health, and Public Health Service (P. Hartge, NCI-SEER study); grants R01 
CA92153 and P50 CA97274, National Institutes of Health (J.R. Cerhan, Mayo Clinic); grants R01 CA45614, R03 
CA89745, R01 CA87014, NCI 263-MQ-701711, U01 CA66529, R01 CA1046282 and CA154643, National 
Institutes of Health and National Cancer Institute, and collection of cancer incidence data was supported by the 
California Department of Public Health as part of the statewide cancer reporting program; the NCI’s SEER 
Program under contract HHSN261201000140C awarded to CPIC; and the CDC’s National Program of Cancer 
Registries, under agreement # U58DP003862-01 awarded to the California Department of Public Health (E.A. 
Holly, UCSF); CA62006, National Cancer Institute (T. Zheng, Connecticut); Leukaemia & Lymphoma Research, 
UK (E. Roman, ELCCS); R19-A2364, Lundbeck Foundation Grant, DP 08-155 Danish Cancer Society Grant, 
5R01 CA69669-02 National Institutes of Health, Danish Cancer Research Foundation Grant and Plan Denmark (M. 
Melbye, SCALE-Denmark); 2009/659, the Swedish Cancer Society, 20110209, Stockholm County Council, 02 
6661, Swedish Cancer Society grant and the Strategic Research Program in Epidemiology at Karolinska Institute 
(K.E. Smedby, SCALE-Sweden); QLK4-CT-2000-00422 and FOOD-CT-2006-023103 European Commission; 
CIBERESP, PI11/01810, RCESP C03/09, RTICESP C03/10 and RTIC RD06/0020/0095, the Spanish Ministry of 
Health (grant references), 051210 the Marató de TV3 Foundation, 2009SGR1465 the Agència de Gestió d’Ajuts 
Universitaris i de Recerca – Generalitat de Catalunya (who had no role in the data collection, analysis or 
interpretation of the results); 2014SGR756-F, PI11/01810, PI14/01219 and CM13/00232; NO1-CO-12400, the 
National Institute of Health, the Compagnia di San Paolo—Programma Oncologia, StSch4261 and StSch4420 
grants, the Federal Office for Radiation Protection, DJCLS-R04/08 the José Carreras Leukemia Foundation grant 
(S. de Sanjose, M. Maynadie, EpiLymph studies).
References
1. Willett EV, Morton LM, Hartge P, Becker N, Bernstein L, Boffetta P, et al. Non-Hodgkin 
lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer. 2008 May 
1.122:2062–70. [PubMed: 18167059] 
Kane et al. Page 8
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2. Cerhan JR, Kricker A, Paltiel O, Flowers CR, Wang SS, Monnereau A, et al. Medical History, 
Lifestyle, Family History, and Occupational Risk Factors for Diffuse Large B-Cell Lymphoma: The 
InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monographs. 2014 Aug; 
2014(48):15–25. [PubMed: 25174023] 
3. Larsson SC, Wolk A. Body mass index and risk of non-Hodgkin’s and Hodgkin’s lymphoma: a 
meta-analysis of prospective studies. Eur J Cancer. 2011 Nov.47:2422–30. [PubMed: 21733676] 
4. Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J. Obesity is associated with 
increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. 
Clin Lymphoma Myeloma Leuk. 2014 Apr.14:122–30. [PubMed: 24360912] 
5. Winer DA, Winer S, Chng MHY, Shen L, Engleman EG. B Lymphocytes in obesity-related adipose 
tissue inflammation and insulin resistance. Cell Mol Life Sci. 2014 Mar.71:1033–43. [PubMed: 
24127133] 
6. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF 
and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet 
Oncol. 2006 Jan.7:27–38. [PubMed: 16389181] 
7. Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjosé S, Hughes AM, et al. Tumor 
necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin 
lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010 Feb 1.171:267–76. [PubMed: 
20047977] 
8. Nieters A, Conde L, Slager SL, Brooks-Wilson A, Morton L, Skibola DR, et al. PRRC2A and 
BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph 
consortium. Blood. 2012 Nov 29.120:4645–8. [PubMed: 23047821] 
9. Conroy SM, Maskarinec G, Morimoto Y, Franke AA, Cooney RV, Wilkens LR, et al. Non-hodgkin 
lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the 
multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2013 Mar.22:337–47. [PubMed: 23300021] 
10. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, et al. Immune mechanisms in 
non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with 
non-Hodgkin lymphoma risk factors. Cancer Res. 2007 May 15.67:5042–54. [PubMed: 17510437] 
11. Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, et al. Cytokine polymorphisms in Th1/Th2 
pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood. 2011 Jan 
13.117:585–90. [PubMed: 20952689] 
12. Cerhan JR, Bernstein L, Severson RK, Davis S, Colt JS, Blair A, et al. Anthropometrics, physical 
activity, related medical conditions, and the risk of non-hodgkin lymphoma. Cancer Causes 
Control. 2005 Dec.16:1203–14. [PubMed: 16215871] 
13. Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, et al. Design and 
validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J 
Mol Epidemiol Genet. 2011; 2:95–113. [PubMed: 21686124] 
14. Cerhan JR, Fredericksen ZS, Novak AJ, Ansell SM, Kay NE, Liebow M, et al. A two-stage 
evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin 
lymphoma identifies new susceptibility locus in 6p21.3 region. Cancer Epidemiol Biomarkers 
Prev. 2012 Oct.21:1799–806. [PubMed: 22911334] 
15. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin’s lymphoma 
among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol. 
1999 Aug 15.150:375–89. [PubMed: 10453814] 
16. Morton LM, Holford TR, Leaderer B, Zhang Y, Zahm SH, Boyle P, et al. Alcohol use and risk of 
non-Hodgkin’s lymphoma among Connecticut women (United States). Cancer Causes Control. 
2003 Sep.14:687–94. [PubMed: 14575367] 
17. Willett EV, Smith AG, Dovey GJ, Morgan GJ, Parker J, Roman E. Tobacco and alcohol 
consumption and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2004 Oct.15:771–
80. [PubMed: 15456990] 
18. Chang ET, Hjalgrim H, Smedby KE, Akerman M, Tani E, Johnsen HE, et al. Body mass index and 
risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005 Feb 
2.97:210–8. [PubMed: 15687364] 
Kane et al. Page 9
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
19. Besson H, Brennan P, Becker N, Nieters A, De Sanjosé S, Font R, et al. Tobacco smoking, alcohol 
drinking and non-Hodgkin’s lymphoma: A European multicenter case-control study (Epilymph). 
Int J Cancer. 2006 Aug 15.119:901–8. [PubMed: 16557575] 
20. De Sanjose S, Shah KV, Domingo-Domenech E, Engels EA, Fernandez de Sevilla A, Alvaro T, et 
al. Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J 
Cancer. 2003 Apr 20.104:522–4. [PubMed: 12584752] 
21. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed 
classification of lymphoid neoplasms for epidemiologic research from the Pathology Working 
Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007 Jul 
15.110:695–708. [PubMed: 17389762] 
22. WHO Expert Committee on Physical Status. Physical Status: The Use and Interpretation of 
Anthropometry: Report of a WHO Expert Committee [Internet]. Geneva, Switzerland: World 
Health Organization; 1995. Report No.: 854. Available from: http://whqlibdoc.who.int/trs/
WHO_TRS_854.pdf
23. Richardson DB, Kaufman JS. Estimation of the relative excess risk due to interaction and 
associated confidence bounds. Am J Epidemiol. 2009 Mar 15.169:756–60. [PubMed: 19211620] 
24. Knol MJ, van der Tweel I, Grobbee DE, Numans ME, Geerlings MI. Estimating interaction on an 
additive scale between continuous determinants in a logistic regression model. Int J Epidemiol. 
2007 Oct.36:1111–8. [PubMed: 17726040] 
25. Troy JD, Hartge P, Weissfeld JL, Oken MM, Colditz GA, Mechanic LE, et al. Associations 
between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Epidemiol. 2010 Jun 
15.171:1270–81. [PubMed: 20494998] 
26. Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, et al. Metabolic factors and 
blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann 
Hematol. 2012 Oct.91:1519–31. [PubMed: 22588328] 
27. Murphy F, Kroll ME, Pirie K, Reeves G, Green J, Beral V. Body size in relation to incidence of 
subtypes of haematological malignancy in the prospective Million Women Study. Br J Cancer. 
2013 Jun 11.108:2390–8. [PubMed: 23640394] 
28. Bertrand KA, Giovannucci E, Zhang SM, Laden F, Rosner B, Birmann BM. A prospective analysis 
of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. 
Cancer Prev Res (Phila). 2013 Aug.6:864–73. [PubMed: 23803416] 
29. Patel AV, Diver WR, Teras LR, Birmann BM, Gapstur SM. Body mass index, height and risk of 
lymphoid neoplasms in a large United States cohort. Leuk Lymphoma. 2013 Jun.54:1221–7. 
[PubMed: 23098244] 
30. Britton JA, Khan AE, Rohrmann S, Becker N, Linseisen J, Nieters A, et al. Anthropometric 
characteristics and non-Hodgkin’s lymphoma and multiple myeloma risk in the European 
Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica. 2008 Nov.93:1666–
77. [PubMed: 18835833] 
31. Maskarinec G, Erber E, Gill J, Cozen W, Kolonel LN. Overweight and obesity at different times in 
life as risk factors for non-Hodgkin’s lymphoma: the multiethnic cohort. Cancer Epidemiol 
Biomarkers Prev. 2008 Jan.17:196–203. [PubMed: 18187389] 
32. Kanda J, Matsuo K, Inoue M, Iwasaki M, Sawada N, Shimazu T, et al. Association of 
anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a 
Japanese population: a population-based cohort study. Cancer Epidemiol Biomarkers Prev. 2010 
Jun.19:1623–31. [PubMed: 20501768] 
33. Lu Y, Prescott J, Sullivan-Halley J, Henderson KD, Ma H, Chang ET, et al. Body size, recreational 
physical activity, and B-cell non-Hodgkin lymphoma risk among women in the California teachers 
study. Am J Epidemiol. 2009 Nov 15.170:1231–40. [PubMed: 19822569] 
34. Pylypchuk RD, Schouten LJ, Goldbohm RA, Schouten HC, van den Brandt PA. Body mass index, 
height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol. 2009 Aug 
1.170:297–307. [PubMed: 19478235] 
Kane et al. Page 10
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
35. Kabat GC, Kim MY, Jean-Wactawski-Wende, Bea JW, Edlefsen KL, Adams-Campbell LL, et al. 
Anthropometric factors, physical activity, and risk of non-Hodgkin’s lymphoma in the Women’s 
Health Initiative. Cancer Epidemiol. 2012 Feb.36:52–9. [PubMed: 21816698] 
36. Kelly JL, Fredericksen ZS, Liebow M, Shanafelt TD, Thompson CA, Call TG, et al. The 
association between early life and adult body mass index and physical activity with risk of non-
Hodgkin lymphoma: impact of gender. Ann Epidemiol. 2012 Dec.22:855–62. [PubMed: 
23146413] 
37. Song Y-M, Sung J, Ha M. Obesity and risk of cancer in postmenopausal Korean women. J Clin 
Oncol. 2008 Jul 10; 26(20):3395–402. [PubMed: 18612154] 
38. Söderberg KC, Kaprio J, Verkasalo PK, Pukkala E, Koskenvuo M, Lundqvist E, et al. Overweight, 
obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur 
J Cancer. 2009 May.45:1232–8. [PubMed: 19091543] 
39. Ali A, Al-Belushi BS, Waly MI, Al-Moundhri M, Burney IA. Dietary and lifestyle factors and risk 
of non-hodgkin’s lymphoma in Oman. Asian Pac J Cancer Prev. 2013; 14:841–8. [PubMed: 
23621249] 
40. Mekinian A, Tamouza R, Pavy S, Gestermann N, Ittah M, Mariette X, et al. Functional study of 
TNF-α promoter polymorphisms: literature review and meta-analysis. Eur Cytokine Netw. 2011 
Jun.22:88–102. [PubMed: 21768061] 
41. Weichhaus M, Broom I, Bermano G. The molecular contribution of TNF-α in the link between 
obesity and breast cancer. Oncol Rep. 2011 Feb.25:477–83. [PubMed: 21165572] 
42. Nair S, Nguyen H, Salama S, Al-Hendy A. Obesity and the Endometrium: Adipocyte-Secreted 
Proinflammatory TNF α Cytokine Enhances the Proliferation of Human Endometrial Glandular 
Cells. Obstet Gynecol Int. 2013; 2013:368543. [PubMed: 24288542] 
43. Alemán JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ, Holt PR. Mechanisms of obesity-
induced gastrointestinal neoplasia. Gastroenterology. 2014 Feb.146:357–73. [PubMed: 24315827] 
44. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-
Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition 
approach. Biochim Biophys Acta. 2011 Jun.1807:664–78. [PubMed: 21111705] 
45. García-Closas M, Thompson WD, Robins JM. Differential misclassification and the assessment of 
gene-environment interactions in case-control studies. Am J Epidemiol. 1998 Mar 1.147:426–33. 
[PubMed: 9525528] 
46. Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, et al. Increased body mass index 
is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. 
J Clin Oncol. 2012 Sep 10.30:3217–22. [PubMed: 22649138] 
47. Connor Gorber S, Tremblay M, Moher D, Gorber B. A comparison of direct vs. self-report 
measures for assessing height, weight and body mass index: a systematic review. Obes Rev. 2007 
Jul.8:307–26. [PubMed: 17578381] 
48. Yu Z, Han S, Cao X, Zhu C, Wang X, Guo X. Genetic polymorphisms in adipokine genes and the 
risk of obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2012 Feb.20:396–
406. [PubMed: 21660081] 
49. World Health Organization. Global Database on Body Mass Index an interactive surveillance tool 
for monitoring nutrition transition [Internet]. World Health Organization; 2006. [cited 2015 Feb 
4]. Available from: http://apps.who.int/bmi/index.jsp
50. Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG. Cytokine SNPs: Comparison of 
allele frequencies by race and implications for future studies. Cytokine. 2009 May.46:236–44. 
[PubMed: 19356949] 
51. Cerhan JR, Berndt SI, Vijai J, Ghesquières H, McKay J, Wang SS, et al. Genome-wide association 
study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014 
Sep 28.
Kane et al. Page 11
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kane et al. Page 12
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f c
as
e-
co
nt
ro
l s
tu
di
es
 in
cl
ud
ed
 in
 th
e 
po
ol
ed
 a
na
ly
sis
.
St
ud
y
Lo
ca
tio
n
Y
ea
rs
 o
f D
ia
gn
os
is
A
ge
 R
an
ge
C
as
es
 (N
=5
84
4)
C
on
tr
ol
s (
N=
61
67
)
N
Pa
rt
ic
ip
at
io
n 
(%
)
So
ur
ce
N
Pa
rt
ic
ip
at
io
n 
(%
)
N
CI
-S
EE
R(
12
)
D
et
ro
it,
 M
ic
hi
ga
n;
 Io
w
a;
 
Lo
s A
ng
el
es
, C
al
ifo
rn
ia
; 
Se
at
tle
, W
as
hi
ng
to
n,
 U
SA
19
98
–2
00
1
20
–7
0
89
5
76
<
65
 y
ea
rs
 R
an
do
m
 d
ig
it 
di
al
lin
g;
 
65
+ 
ye
ar
s r
an
do
m
 se
le
ct
io
n 
fro
m
 
Ce
nt
er
s f
or
 M
ed
ic
ar
e 
an
d 
M
ed
ic
ai
d 
Se
rv
ic
es
, s
tra
tif
ie
d 
by
 
st
ud
y 
ar
ea
, a
ge
, s
ex
 a
nd
 ra
ce
68
6
52
M
ay
o 
Cl
in
ic
 P
ha
se
s 1
–
3(1
3,
14
)
Io
w
a,
 W
isc
on
sin
, 
M
in
ne
so
ta
, U
SA
20
02
–2
00
8
18
+
88
7
69
Fr
eq
ue
nc
y 
m
at
ch
ed
 b
y 
ag
e,
 se
x 
an
d 
co
un
ty
 o
f r
es
id
en
ce
10
46
69
U
CS
F(
15
)
Sa
n 
Fr
an
ci
sc
o,
 U
SA
19
88
–1
99
5
21
–7
4
30
9
72
R
an
do
m
 d
ig
it 
di
al
lin
g,
 fr
eq
ue
nc
y 
m
at
ch
ed
 b
y 
ag
e,
 se
x,
 a
nd
 c
ou
nt
y 
of
 
re
sid
en
ce
68
5
78
Co
nn
ec
tic
ut
(16
)
Co
nn
ec
tic
ut
 U
SA
19
95
–2
00
1
21
–8
4 
w
om
en
 o
nl
y
48
3
72
W
om
en
 o
nl
y:
 <
65
 y
ea
rs
 R
an
do
m
 
D
ig
it 
D
ia
lli
ng
; 6
5+
 y
ea
rs
 ra
nd
om
 
se
le
ct
io
n 
fro
m
 C
en
te
rs
 fo
r 
M
ed
ic
ar
e 
an
d 
M
ed
ic
ai
d 
Se
rv
ic
es
. 
Fr
eq
ue
nc
y 
m
at
ch
ed
 w
ith
in
 5
 y
ea
rs
 
o
f a
ge
55
3
R
D
D
:6
9;
 C
M
M
S:
47
U
K
(17
)
Y
or
ks
hi
re
, L
an
ca
sh
ire
, 
So
ut
h 
La
ke
la
nd
 a
nd
 p
ar
ts 
o
f S
ou
th
w
es
t E
ng
la
nd
19
98
–2
00
3
16
–6
9
62
6
70
R
an
do
m
 se
le
ct
io
n 
fro
m
 g
en
er
al
 
pr
ac
tic
e 
lis
ts,
 in
di
vi
du
al
ly
 m
at
ch
ed
 
by
 a
ge
, s
ex
 a
nd
 re
gi
on
 o
f r
es
id
en
ce
78
4
69
SC
A
LE
 D
en
m
ar
k(1
8)
D
en
m
ar
k
20
00
–2
00
2
18
–7
4
76
8
81
R
an
do
m
 se
le
ct
io
n 
fro
m
 p
op
ul
at
io
n 
re
gi
ste
r, 
fre
qu
en
cy
 m
at
ch
ed
 b
y 
se
x 
an
d 
ag
e
74
5
71
SC
A
LE
 S
w
ed
en
(18
)
Sw
ed
en
20
00
–2
00
2
18
–7
4
15
28
81
R
an
do
m
 se
le
ct
io
n 
fro
m
 p
op
ul
at
io
n 
re
gi
ste
r, 
fre
qu
en
cy
 m
at
ch
ed
 b
y 
se
x 
an
d 
ag
e
11
16
71
Ep
iL
ym
ph
 F
ra
nc
e(1
9)
A
m
ie
ns
, D
ijo
n a
nd
 
M
on
tp
el
lie
r
20
00
–2
00
3
18
–8
0
85
91
H
os
pi
ta
l c
on
tro
ls 
m
at
ch
ed
 b
y 
ag
e 
(±
5 y
ea
rs)
, s
ex
 an
d s
tud
y r
eg
ion
12
9
74
Ep
iL
ym
ph
 S
pa
in
(20
)
B
ar
ce
lo
na
, T
or
to
sa
, R
eu
s 
an
d 
M
ad
rid
19
98
–2
00
2
18
–8
0
26
3
82
H
os
pi
ta
l c
on
tro
ls 
m
at
ch
ed
 b
y 
ag
e 
(±
5 y
ea
rs)
, s
ex
 an
d s
tud
y r
eg
ion
42
3
96
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Kane et al. Page 13
Table 2
Demographics of cases and controls.
Cases
N(%)
Controls
N(%)
Total 5844(100) 6167(100)
Diagnosis
 B-cell 5241(90) -
  DLBCL 1643(28) -
  Follicular 1344(23) -
  CLL/SLL 1089(19)
  Other 1165(20) -
 T-cell 342(6) -
 Not Otherwise Specified 261(3) -
Sex
Male 3088(53) 3101(50)
Female 2756(47) 3066(50)
Age
<46 803(14) 1128(18)
46–55 1319(23) 1236(20)
56–65 1824(31) 1710(28)
>65 1898(32) 2093(34)
Socioeconomic Status
Low 2130(36) 2045(33)
Medium 1825(31) 1945(32)
High 1860(32) 2145(35)
Not Known 29(0.5) 32(0.5)
BMI(kg m−2)
Underweight: <18.5 57(1) 75(1)
Normal weight: 18.5–<25 2573(44) 2851(46)
Overweight: 25–<30 2214(38) 2275(37)
Obese: ≥30 1000(17) 966(16)
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